Saptalis Pharmaceuticals

Saptalis Pharmaceuticals develops, manufactures, and commercializes niche generic prescription and innovative specialty pharmaceutical products. The company has a growing commercial portfolio of FDA-approved oral liquid and topical medications using ANDA and NDA pathways. Notable recent launches include LIKMEZ™—the first ready-made metronidazole suspension for patients with dysphagia—developed using Appili’s taste-masking technology. Saptalis recently expanded its pipeline by acquiring multiple ANDAs/NDA assets from Akorn Holding Company. The company operates state-of-the-art R&D labs and cGMP-compliant manufacturing facilities in Hauppauge, NY.